InfuSystem Pain Management, InfuBLOCK, Treatment, Pump, Health Care Professionals, Healthcare, Clinician, Peripheral Nerve Block Solution, Post-Op Pain Control, Infusion

Pain Management

Endura-KT™ Injectable For Postsurgical Non-Opioid Pain Management. Brought to you by InfuBLOCK™.

Endura-KT is an opioid and preservative-free local anesthetic compound. Endura-KT contains three components, which, when combined, mix into a Lidocaine, Tetracaine and Epinephrine injection for postoperative pain relief. This combination of three well-known, extremely safe, low-toxic drugs provides an anesthetic designed to deliver an opioid-free postoperative solution.

Endura-KT provides a long-lasting pain management solution for various pain management applications. The local anesthetic compound may be suitable for a variety of surgical procedures and plane blocks, longer-acting local infiltration anesthesia, and local or regional pain management.

Due to the dilute concentration of the components, the combined product has low toxicity. This allows higher volume dosing for volume/plane blocks to ensure full coverage of the affected nerves.2,3

Pain-Control Applications: Use for incisional infiltration, major and minor regional nerve blocks, soft tissue infiltration, subcutaneous, epidural and intra-articular injection.

What is Endura-KT Injectable?

(Tetracaine 0.2%, Lidocaine 0.4%, Epinephrine 1:1000)

  • Endura-KT is a local anesthesia compound that offers a solution for non-opioid pain relief. Endura-KT provides ultra-long acting, safe pain relief for post-operative care.
  • Endura-KT contains two components, which, when combined, mixes into a preservative-free, patented local anesthetic compound.
  • Endura-KT consists of one preloaded Luer-Lock syringe with an 18g mixing needle containing 0.2mL of Epinephrine 1:1000, and one vial containing 50mL of Tetracaine and Lidocaine. Combining these two components results in a solution of 0.2% Tetracaine and 0.4% Lidocaine with Epinephrine 1:250,000.
  • The maximum recommended dose is 1.5mL/kg IBW.1


  • Opioid-Free Pain Relief
  • A Versatile Post-Operative Pain Relief Solution
  • Low-Toxicity Formula
  • Increased Comfort With Minimal Side Effects
  • Potential Reduced Need for Narcotic Prescriptions
  • Long-Lasting Pain Relief

Cost Efficient and Available Throughout the U.S. to Improve the Quality of Life for All Patients

Increase Patients' Level of Comfort with Fewer Side Effects.

Enhanced Recovery After Surgery

Endura-KT Injectable addresses the demand for non-opioid pain control by providing safe and effective pain relief for patients after surgery.

Endura-KT includes:

    One Pre-Loaded Luer-Lock Syringe Containing 0.2mL of Preservative-Free Epinephrine 1:1000, USP (0.2mg/0.2mL)

    One Sterile Injection Vial Containing 50mL Preservative-Free 0.4% Lidocaine HCI with 0.2% Tetracaine HCI

Combining these two components results in a solution of 0.2% Tetracain and 0.4% Lidocaine with Epinephrine 1:250,000. A maximum recommended dose is 1.5mL/kg IBW.

  • Alcohol Prep Pad
  • 18G 1” Blunt Needle
  • Green Transfer Label Sticker
  • Directions for Use Insert

Download Literature

*Endura-KT is not recommended for topical use or for spinal anesthesia. This product is an off-label use of three long-available and extremely safe anesthetics. Medications may only be ordered by health care providers when it is determined that the product is clinically significant over other commercially available products.

FDA Disclaimer:
This product has not been evaluated or approved by the FDA. Nubratori RX Products are produced and lawfully sold in the USA, under the FDA Structured Product Listing Marketing Category #Cl81659 “Outsourcing Facility Compounded Human Drug Product” (Exempt from Approval Requirements). Under the Drug Quality and Security Act of 2013 enacted by Congress, human drug products compounded by an outsourcing facility, such as Nubratori RX, are exempt from the following three sections of the FD&C Act: section 505 (21 U.S.C. 355).

A. Concerning the approval of drugs under new drug applications or abbreviated new drug applications); section 502(f)(l) (21 U.S.C. 352(f)(l).
B. Concerning the labeling of drugs with adequate directions for use.
C. Concerning Drug Supply Chain Security Requirements: section 582 (21 U.S.C. 360eee-1).

1. Local Anesthetics. Ian K McLeod, MD; Chief Editor: Arlen D Meyers, MD, MBA et al. Updated: Mar 18, 2015.
2. Epinephrine prolongs duration of subcutaneous infiltration of local anesthesia in a dose-related manner. Correlation with magnitude of vasoconstriction. S Liu, R L Carpenter, A A Chiu, T J McGill, S A Mantell. Regional Anesth. Sep-Oct 1995; 20(5):378-84.
3. Laparoscopic-Guided Transversus Abdominis Plane Block for Colorectal Surgery, Joanne Favuzza, D.O., Conor P. Delaney, M.D. Dis Colon Rectum 2013; 56: 389–391DOI: 10.1097/DCR.0b013e318280549b © The ASCRS 2013.
4. The Opioid Epidemic: By the Numbers.
5. New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults. Chad M. Brummett, MD, et al. JAMA Surg. Published online April 12, 2017. doi:10.1001/jamasurg.2017.0504.
6. Benefit and risks of local anesthetics in infants and children. Gunter JB. Paediatric Drugs. 2002;4(10):649-72.
7. Evidence-based practice supports adopting ERAS protocols. OR Manager Vol. 33 No. 5 May 2017. Brydges G.
8. On the Mechanism by Which Epinephrine Potentiates Lidocaine’s Peripheral Nerve Block. Catherine J. Sinnott, B.A.; Lawrence P. Cogswell, Ph.D.; Anthony Johnson, B.S.; Gary R. Strichartz, Ph.D. Anesthesiology January 2003, Vol. 98, 181–188.
9. Anesthesiology. 1981 Mar; 54(3):177-81. Mixtures of local anesthetics are no more toxic than the parent drugs. de Jong RH, Bonin JD.

© Copyright 2023 Endura-KT, All Rights Reserved.